TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05294354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise group (AE)
Description: The participants will ride the cycle ergometer for 35 minutes. The training consisted of a 5-minute warm-up period followed by 25 minutes of moderate exercise and a 5-minute recovery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise with virtual reality group (AE-VR)
Description: The participants will receive the 3D VR training program and ride the cycle ergometer at the same time. The training protocol is similar to the aerobic exercise group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined exercise group (CE)
Description: The intervention consists of 5-minutes aerobic warm-up, 25-minutes bodyweight exercise, and 5-minutes mindfulness meditation for recovery. The participants will follow the video to do the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will watch a 35-min video about exercise science.
Study: NCT06200649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
Study: NCT05232006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib, once daily
Study: NCT06154655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-zine
Description: Health education will be delivered through an electronic magazine
Study: NCT05697263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodization of training
Description: Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodization of training
Description: Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodization of training
Description: Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
Study: NCT04967222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal by Distancing
Description: Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Downregulate Condition
Description: Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
Study: NCT05440396

Intervention type: DIAGNOSTIC_TEST
Intervention: Photographs collection phase
Description: Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling.
Study: NCT05555355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena Plus 125 Therapy Unit
Description: The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spine surgery
Description: Patients will receive spine surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery
Description: Patients will receive spine surgery
Study: NCT03311451

Intervention type: DEVICE
Group type: OTHER
Intervention: C2 CryoBalloon 180° Ablation System
Description: The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
Study: NCT05902078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol capsules
Description: Oral eldecalcitol 0.75μg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: Oral calcitriol 0.5μg daily
Study: NCT05662696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raabta Telemonitoring Program (Mobile Application)
Description: Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
Study: NCT05010954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028 50mg group
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg group
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
Study: NCT06131333

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation
Description: PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
Study: NCT06515600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.
Description: All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.
Description: All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min.
Study: NCT02177721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of samples
Description: Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA.
Study: NCT05151120

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
Study: NCT04616248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Flt3 Ligand
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Flt3 Ligand
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given SC
Study: NCT05828082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo U/S
Study: NCT05744570

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Regional anesthesia for labor pain

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Regional anesthesia for labor pain
Study: NCT06428825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BAY3283142
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BAY3283142
Description: oral administration
Study: NCT04993833

Intervention type: DEVICE
Intervention: NPi-200 and NPi-300 pupillometers
Description: Device which measures PLR.

Intervention type: DEVICE
Intervention: NPi-200 and NPi-300 pupillometers
Description: Device which measures PLR.
Study: NCT06034535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD62L depleted donor lymphocyte infusion
Description: Intravenous infusion of CD62L depleted donor lymphocytes
Study: NCT05245019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cardamom
Description: cardamom is used as a flavoring agent in foods as well as for treating various cardiovascular, gastrointestinal, and neural problems

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fennel
Description: fennel is Known for its anti-inflammatory, anti-spasmodic, and analgesic properties, it is also widely used for treating gastroenteritis and indigestion.
Study: NCT06427291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes virus T3011 injection
Description: T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
Study: NCT05619302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8 PET/MRI
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [68Ga]CBP8 PET/MRI
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]CBP8 PET/MRI
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [68Ga]CBP8 PET/MRI
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
Study: NCT05905393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery
Description: Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: preoperative stimulation of the efferent loop with only physiological saline
Description: Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
Study: NCT04255147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells
Description: Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
Study: NCT04682704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym
Description: Tragus stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parasym
Description: Tragus stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parasym
Description: Tragus stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parasym
Description: Tragus stimulation
Study: NCT05723354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary block guided by ultrasound
Description: axillary block using local anesthetics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary block guided by ultrasound
Description: axillary block using local anesthetics
Study: NCT06035796

Intervention type: DEVICE
Intervention: tNGS
Description: By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
Study: NCT05732662

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 24-50Gy/8-12.5Gy/3-4f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10 mg/kg,q3w
Study: NCT05579990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Description: 10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
Study: NCT04987489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat tablets
Description: Etavopivat 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat tablets
Description: Etavopivat 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat tablets
Description: Etavopivat 400 mg once daily
Study: NCT06222697

Intervention type: DRUG
Intervention: Damoctocog-alfa-pegol (Jivi, BAY94-9027)
Description: Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
Study: NCT05393401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOP1k
Description: Photoplethysmographic records
Study: NCT06578117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision Training and Learning Task
Description: Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision Training and Learning Task
Description: Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard.
Study: NCT06402357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal One high intensity focused ultrasound device
Description: Participants will be treated with one session of high intensity focused ultrasound using the Focal One device.
Study: NCT05638022

Intervention type: DIAGNOSTIC_TEST
Intervention: Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test
Description: Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA testing
Description: DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
Study: NCT04744571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary wires. or coronary balloons
Description: all species of coronary wires, or plain balloons

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coronary wires. or coronary balloons
Description: all species of coronary wires, or plain balloons

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug-coated balloon
Description: Drug-coated balloon including all sizes and all brands

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting stent
Description: Drug-eluting stent including all sizes and all brands
Study: NCT05622825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
Study: NCT04881461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-grass mix SLIT-drops
Description: Sublingual allergy immunotherapy drops, for daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo